“Exelixis (EXEL) is maintaining the previously provided financial guidance for fiscal year 2025. Net product and total revenues guidance do not currently reflect any revenues resulting from a potential U.S. regulatory approval and commercial launch of CABOMETYX for the treatment of patients with previously treated advanced neuroendocrine tumors. The U.S. Food and Drug Administration is currently reviewing Exelixis’ supplemental New Drug Application for this proposed indication, with a Prescription Drug User Fee Act – PDUFA – target action date of April 3,” the company stated.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- EXEL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Exelixis price target raised to $43 from $42 at Truist
- Exelixis upgraded to Overweight from Equal Weight at Morgan Stanley
- Exelixis announces results from expansion cohort of phase 1b/2 STELLAR-001
- Exelixis reports on subgroup analysis of Phase 3 CABINET study